InnoCare Pharma (9969) Q4 2025 earnings summary

Executive summary

• Achieved first full-year profitability in 2025 with net profit of RMB 644.2 million, reversing a prior loss, driven by strong drug sales, licensing revenue, and 135% year-over-year revenue growth.

• Total revenue reached RMB 2.38 billion, up 135.3% year-over-year, with drug sales at RMB 1.44 billion, led by orelabrutinib and tafasitamab launches.

• Maintained robust cash position of RMB 7.8 billion at year-end, supporting ongoing R&D, commercialization, and global expansion.

• Advanced internationalization with major global partnerships and licensing deals, including Zenas BioPharma and Prolium, with total BD deal value exceeding $2.5 billion.

• Significant progress in hematologic oncology, autoimmune diseases, and solid tumors, with multiple regulatory approvals and late-stage clinical advancements.

Financial highlights

• Gross profit increased 150.7% to RMB 2,183.8 million; gross margin rose to 92.0% from 86.3% in 2024, mainly due to high-margin collaboration revenue.

• Diluted EPS was RMB 0.38, turning positive from a loss per share of RMB 0.26 in 2024.

• R&D expenses were RMB 952 million, up 16.9% year-over-year, reflecting strategic investment in innovation.

• Positive operating cash flow achieved for the first time.

• Adjusted profit for the year was RMB 675.4 million, excluding non-cash items.

Outlook and guidance

• Management anticipates 2026 to be catalyst-rich, with multiple late-stage assets approaching regulatory submissions and commercialization.

• Drug sales expected to grow by more than 35% in 2026, driven by new indications and expanded hospital coverage.

• R&D expenses projected to grow around 20% in 2026, with no near-term financing pressure.

• Continued focus on globalization, selective out-licensing, and regional partnerships to maximize asset value.

• Multiple major product approvals and NDA submissions anticipated in the next two to three years.